168
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Development of a Measure to Assess Attitudes Towards Nasal versus Autoinjector Glucagon Delivery Devices for Treatment of Severe Hypoglycemia

, ORCID Icon, , , , , , , , ORCID Icon & show all
Pages 3601-3615 | Received 07 Jun 2022, Accepted 17 Sep 2022, Published online: 21 Nov 2022

References

  • Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association workgroup on hypoglycemia. Diabetes Care. 2005;28:1245–1249. doi:10.2337/diacare.28.5.1245
  • Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384–1395. doi:10.2337/dc12-2480
  • American Diabetes Association. Diabetes advocacy: standards of medical care in diabetes 2020. Diabetes Care. 2020;43(Suppl. 1):S203–S204. doi:10.2337/dc20-S016
  • UK Hypoglycaemia Study Groups. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140–1147. doi:10.1007/s00125-007-0599-y
  • Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014;10:711–712. doi:10.1038/nrendo.2014.170
  • Edridge CL, Dunkley AJ, Bodicoat DH, et al. Prevalence and incidence of hypoglycaemia in 532,542 people with type 2 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies. PLoS One. 2015;10(6):e0126427. doi:10.1371/journal.pone.0126427
  • Goldstein D, Chodick G, Shalev V, Thorsted BL, Elliott L, Karasik A. Use of healthcare services following severe hypoglycemia in patients with diabetes: analysis of real-world data. Diabetes Ther. 2016;7(2):295–308. doi:10.1007/s13300-016-0169-8
  • McEwan P, Larsen Thorsted B, Wolden M, Jacobsen J, Evans M. Healthcare resource implications of hypoglycemia-related hospital admissions and inpatient hypoglycemia: retrospective record-linked cohort studies in England. BMJ Open Diabetes Res Care. 2015;3(1):e000057. doi:10.1136/bmjdrc-2014-000057
  • Bronstone A, Graham C. The potential cost implications of averting severe hypoglycemic events requiring hospitalization in high-risk adults with type 1 diabetes using real-time continuous glucose monitoring. J Diabetes Sci Technol. 2016;10(4):905–913. doi:10.1177/1932296816633233
  • American Diabetes Association. 10 Microvascular complications and foot care: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S105–s118. doi:10.2337/dc18-S010
  • Pontiroli AE, Ceriani V. Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality? Diabetes Obes Metab. 2018;20(8):1812–1816. doi:10.1111/dom.13317
  • Yale JF, Dulude H, Egeth M, et al. Faster use and fewer failures with needle-free nasal glucagon versus injectable glucagon in severe hypoglycemia rescue: a simulation study. Diabetes Technol Ther. 2017;19(7):423–432. doi:10.1089/dia.2016.0460
  • Harris G, Diment A, Sulway M, Wilkinson M. Glucagon administration - undervalued and undertaught. Pract Diab Int. 2001;18(1):22–25. doi:10.1002/pdi.138
  • Deacon B, Abramowitz J. Fear of needles and vasovagal reactions among phlebotomy patients. J Anxiety Disord. 2006;20(7):946–960. doi:10.1016/j.janxdis.2006.01.004
  • Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults: prevalence and associations. Am J Trop Med Hyg. 2003;68(3):341–344. doi:10.4269/ajtmh.2003.68.341
  • Pfutzner A, Schipper C, Niemeyer M, et al. Comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skills. J Diabetes Sci Technol. 2012;6(4):910–916. doi:10.1177/193229681200600423
  • Taddio A, Ipp M, Thivakaran S, et al. Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. Vaccine. 2012;30(32):4807–4812. doi:10.1016/j.vaccine.2012.05.011
  • Rickels MR, Ruedy KJ, Foster NC, et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care. 2016;39(2):264–270. doi:10.2337/dc15-1498
  • Pharmaceuticals X. Xeris pharmaceuticals achieves phase 3 milestones of its ready-to-use glucagon rescue pen for the treatment of severe hypoglycemia. Xeris Pharmaceuticals, Inc.; 2018. Available from: https://globenewswire.com/news-release/2018/02/15/1349229/0/en/Xeris-Pharmaceuticals-Achieves-Phase-3-Milestones-of-its-Ready-to-Use-Glucagon-Rescue-Pen-for-The-Treatment-of-Severe-Hypoglycemia.htm. Accessed February 15, 2018.
  • Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39–48. doi:10.2147/PPA.S24752
  • Stewart KD, Johnston JA, Matza LS, et al. Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence. 2016;10:1385–1399. doi:10.2147/PPA.S101821
  • Prevention CfDCa. Collaborating Center for Questionnaire Design and Evaluation Research (CCQDER). National Center for Health Statisitcs Web site; 2014. Available from: https://www.cdc.gov/qdrl/b2questevalu/QECognInter210.htm. Accessed September 20, 2022.
  • Matfin G, Van Brunt K, Zimmermann AG, Threlkeld R, Ignaut DA. Safe and effective use of the once weekly dulaglutide single-dose pen in injection-naive patients with type 2 diabetes. J Diabetes Sci Technol. 2015;9(5):1071–1079. doi:10.1177/1932296815583059
  • Matza LS, Boye KS, Stewart KD, Paczkowski R, Jordan J, Murray LT. Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ). J Patient-Rep Outcomes. 2018;2:43. doi:10.1186/s41687-018-0068-z
  • Yu M, Brunt KV, Milicevic Z, Varnado O, Boye KS. Patient-reported outcomes in patients with type 2 diabetes treated with dulaglutide added to titrated insulin glargine (AWARD-9). Clin Ther. 2017;39(11):2284–2295. doi:10.1016/j.clinthera.2017.10.002
  • Bajpai SK, Cambron-Mellott MJ, Peck E, et al. Perceptions about glucagon delivery devices for severe hypoglycemia: qualitative research with patients, caregivers, and acquaintances. Clin Ther. 2019;41(10):2073–2089.e2076. doi:10.1016/j.clinthera.2019.08.006
  • Altman DG, Bland JM. Statistics notes. Units of analysis. BMJ. 1997;314(7098):1874. doi:10.1136/bmj.314.7098.1874
  • Nunnally JC. Psychometric Theory. 2nd Ed. New York: McGraw-Hill; 1978.
  • Briggs SR, Cheek JM. The role of factor analysis in the development and evaluation of personality scales. J Pers. 1986;54(1):106–148. doi:10.1111/j.1467-6494.1986.tb00391.x
  • Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12. doi:10.1186/1477-7525-2-12
  • Peterson RA, Wilson WR. Measuring customer satisfaction: fact and artifact. Acad Mark Sci Rev. 1992;20(1):61. doi:10.1007/BF02723476
  • Andrew S, Salamonson Y, Everett B, Halcomb EJ, Davidson PM. Beyond the ceiling effect: using a mixed methods approach to measure patient satisfaction. Int J Mult Res Approaches. 2011;5(1):52–63. doi:10.5172/mra.2011.5.1.52
  • Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims; 2009.
  • Matza LS, Stewart KD, Paczkowski R, Coyne KS, Currie B, Boye KS. Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ). J Patient-Rep Outcomes. 2018;2:44. doi:10.1186/s41687-018-0064-3